LY334370

☆ Save On Wikipedia ↗
LY-334370
Clinical data
Other namesLY334370; LY-334,370
Drug classSerotonin 5-HT1F receptor agonist
ATC code
  • None
Identifiers
  • 4-fluoro-N-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]benzamide
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC21H22FN3O
Molar mass351.425 g·mol−1
3D model (JSmol)
  • CN1CCC(CC1)C2=CNC3=C2C=C(C=C3)NC(=O)C4=CC=C(C=C4)F
  • InChI=1S/C21H22FN3O/c1-25-10-8-14(9-11-25)19-13-23-20-7-6-17(12-18(19)20)24-21(26)15-2-4-16(22)5-3-15/h2-7,12-14,23H,8-11H2,1H3,(H,24,26)
  • Key:MDMJLMDBRQXOOI-UHFFFAOYSA-N

LY-334370 is a selective serotonin 5-HT1F receptor agonist[1] of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches.[2] The drug showed efficacy in a phase II clinical trial[3] but further development was halted due to toxicity detected in animals.[4] It is closely related to tryptamines like the psychedelic drug dimethyltryptamine (DMT), but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.[5] The drug's affinities for various serotonin receptors have been reported.[6]

See also

References

  1. Dupuis DS, Colpaert FC, Pauwels PJ (1998). "G-protein activation at 5-HT1A receptors by the 5-HT1F ligand LY-334,370 in guinea-pig brain sections and recombinant cell lines". Br. J. Pharmacol. 124 (2): 283–90. doi:10.1038/sj.bjp.0701832. PMC 1565387. PMID 9641544.
  2. Shepheard S, Edvinsson L, Cumberbatch M, Williamson D, Mason G, Webb J, et al. (1999). "Possible antimigraine mechanisms of action of the 5HT1F receptor agonist LY-334,370". Cephalalgia. 19 (10): 851–8. doi:10.1046/j.1468-2982.1999.1910851.x. PMID 10668103. S2CID 8439008.
  3. Goldstein DJ, Roon KI, Offen WW, Ramadan NM, Phebus LA, Johnson KW, et al. (2001). "Selective seratonin 1F (5-HT1F) receptor agonist LY334370 for acute migraine: a randomised controlled trial". Lancet. 358 (9289): 1230–4. doi:10.1016/S0140-6736(01)06347-4. PMID 11675061. S2CID 39926402.
  4. Ramadan NM, Buchanan TM (2006). "New and future migraine therapy". Pharmacol. Ther. 112 (1): 199–212. doi:10.1016/j.pharmthera.2005.04.010. PMID 16797716.
  5. "4-Fluoro-N-(3-(1-methyl-4-piperidinyl)-1H-indol-5-yl)benzamide". PubChem. Retrieved 29 July 2025.
  6. Roberts C, Price GW, Middlemiss DN (November 2001). "Ligands for the investigation of 5-HT autoreceptor function". Brain Res Bull. 56 (5): 463–469. doi:10.1016/s0361-9230(01)00628-1. PMID 11750791.